DCTH vs IRMD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IRMD Captures Institutional Edge (2โ2 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to iRadimed Corporation (IRMD) driven by superior Valuation, Growth & Margin while DCTH counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, DCTH trades at N/M Forward P/E with 5.2% operating margin (+70.7% YoY revenue) versus IRMD at 35.0x Forward P/E and 32.3% operating margin (+14.2% YoY). In options structure, DCTH sits in BREAKOUT (43rd %ile IV; Dealer Gamma Walls on Pro) against IRMD sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DCTH Revenue | IRMD Revenue | DCTH Op. Margin | IRMD Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $30M | N/A | 19.7% | IRMD |
| FY2019 | N/A | $40M | N/A | 22.5% | IRMD |
| FY2020 | N/A | $30M | N/A | -2.4% | IRMD |
| FY2021 | $0M | $40M | -690.0% | 23.5% | IRMD |
| FY2022 | $0M | $50M | -1245.1% | 29.3% | IRMD |
| FY2023 | $0M | $70M | -1849.0% | 30.6% | IRMD |
| FY2024 | $40M | $70M | -33.4% | 30.0% | IRMD |
| FY2025 | $90M | $80M | 0.8% | 31.2% | IRMD |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | DCTH | IRMD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $743.8M | $1.1B | Larger Scale | IRMD |
| Trailing P/E Ratio Valuation | 133.6x | 45.3x | Lower Multiple | IRMD |
| Forward P/E Ratio Valuation | N/M | 35.0x | Lower Multiple | IRMD |
| Revenue Growth (YoY) Growth | +70.7% | +14.2% | Higher Growth | DCTH |
| Operating Margin (TTM) Profitability | 5.2% | 32.3% | Higher Margin | IRMD |
| Net Profit Margin Profitability | 6.0% | 26.9% | Higher Margin | IRMD |
| Return on Equity (ROE) Capital Efficiency | 5.4% | 23.4% | Higher ROE | IRMD |
| 52-Week Range Position Momentum | 80% ($8โ$23) | 26% ($76โ$108) | Stronger Trend | DCTH |
| Beta / 30D Volatility Risk Regime | 1.63ฮฒ ยท 131% Vol | 0.73ฮฒ ยท 55% Vol | Lower Realized Risk | IRMD |
| Unified Institutional Score Composite Signal | 35.9 / 100 (SELL) | 40.3 / 100 (SELL) | Higher Composite | IRMD |